Table 4.
Peripheral neuropathy and neutropenia AEs by prior anthracycline and/or taxane treatment
| Study 206 (HER2− MBC; Eribulin Only) (N = 56) | Study 208 (HER2+ MBC; Eribulin + Trastuzumab) (N = 52) | |||||||
|---|---|---|---|---|---|---|---|---|
| With prior anthracycline (n = 27) | With prior taxane (n = 26) | With prior anthracycline and taxane (n = 20) | Without prior anthracycline or taxane (n = 23) | With prior anthracycline (n = 11) | With prior taxane (n = 23) | With prior anthracycline and taxane (n = 9) | Without prior anthracycline or taxane (n = 27) | |
| Peripheral neuropathy (SMQ), n (%) | ||||||||
| Grade 1 | 4 (14.8) | 4 (15.4) | 2 (10.0) | 7 (30.4) | 4 (36.4) | 6 (26.1) | 4 (44.4) | 5 (18.5) |
| Grade 2 | 5 (18.5) | 4 (15.4) | 4 (20.0) | 4 (17.4) | 2 (18.2) | 7 (30.4) | 2 (22.2) | 4 (14.8) |
| Grade 3 | 5 (18.5) | 6 (23.1) | 5 (25.0) | 6 (26.1) | 2 (18.2) | 3 (13.0) | 1 (11.1) | 10 (37.0) |
| Grade ≥4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Febrile neutropenia | 2 (7.4) | 2 (7.7) | 1 (5.0) | 1 (4.3) | 0 | 3 (13.0) | 0 | 1 (3.7) |
| Neutropenia | 21 (77.7) | 22 (84.6) | 16 (80.0) | 13 (56.5) | 9 (81.8) | 15 (65.2) | 7 (77.7) | 14 (51.9) |